Incyte (NASDAQ:INCY) is gearing up to announce its quarterly earnings on Tuesday, 2026-02-10. Here’s a quick overview of what investors should know before the release.
Analysts are estimating that Incyte will report an earnings per share (EPS) of $1.83.
Anticipation surrounds Incyte’s announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
Historical Earnings Performance
Last quarter the company beat EPS by $0.73, which was followed by a 1.6% drop in the share price the next day.
Here’s a look at Incyte’s past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 1.53 | 1.34 | 1.03 | 1.55 |
| EPS Actual | 2.26 | 1.57 | 1.16 | 1.43 |
| Price Change % | -2.00 | 0.00 | 4.00 | -3.00 |
Incyte Share Price Analysis
Shares of Incyte were trading at $108.39 as of February 06. Over the last 52-week period, shares are up 64.41%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
Insights Shared by Analysts on Incyte
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Incyte.
With 10 analyst ratings, Incyte has a consensus rating of Outperform. The average one-year price target is $113.4, indicating a potential 4.62% upside.
Peer Ratings Overview
The analysis below examines the analyst ratings and average 1-year price targets of United Therapeutics, Exact Sciences and Genmab, three …